Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a psychedelic drug impacts the substance’s effects. Microdosing refers to consuming a small dose of a recreational dose of a psychedelic, the most commonly used substances being psilocybin and LSD.
The biotech firm announced that its research would focus on assessing and comparing evening and daytime administration of microdoses of LSD.
LSD is a psychedelic drug whose effects include intensified emotions, thoughts and sensory perception. For microdoses, small doses are consumed to obtain the substance’s benefits while minimizing unpleasant side effects. In high doses, LSD can cause auditory and visual hallucinations.
Dr. Kim Kuypers, a Maastricht University associate professor and a low-dose psychedelics expert, will be leading the study. The team of researchers will use digital measurement devices and software to assess the effects of microdoses of LSD on neuroplasticity markers such as regulation of emotions, cognitive performance, immune system response, mood, BDNF plasma levels and different measures of sleep.
Kuypers stated that studying the practice of microdosing on psychedelics began with the basics, including examining if there was a time of day that influenced the effect of these treatments. She explained that they would be studying whether microdosing LSD could cause patterns of thinking to realign in a way that would allow people to access levels of self-awareness that could offer them an enriched experience of life.
Microdosing has become popular in the last few years, with anecdotal evidence from major tech entrepreneurs claiming that psychedelic microdoses can decrease anxiety and boost productivity and creativity. However, the potential for microdosing has yet to be understood fully due to a lack of sufficient evidence.
A recent study conducted by researchers from Imperial College London showed that microdosing may be a placebo. In their conclusion, the researchers noted that the belief that participants had that they were consuming a microdose had a great influence in the improvement of their mental health than the drug itself.
MindMed hopes that its new innovative study design will help discover more evidence to support the claimed benefits of microdosing and investigate safety as well.
Dr. Miri Halperin Wernli, MindMed executive president, stated that the company’s study objective was to offer insight on major parameters that may affect treatments as well as explain the mechanisms behind these small-dose treatments.
Psychedelic science is advancing at a fast pace, and some companies, including Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF), seem poised to bring to market new remedies from these currently prohibited substances.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…
The new FDA voucher program aims to speed approval of drugs aligned with national health…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…